摘要分子诊断对于肝胆肿瘤的临床诊疗有重要意义。专家组在2020年首次发布了《肝胆肿瘤分子诊断临床应用专家共识》，该共识的推出推动了分子诊断技术在肝胆肿瘤临床工作中的规范化应用，提高了临床医师对肝胆肿瘤的诊断与治疗能力。近年，有关肝胆肿瘤的研究逐渐展开，新的研究结果不断公布。专家组结合最新的研究进展在原有共识的基础上更新了共识，聚焦于肝胆肿瘤的靶向和免疫治疗的分子标志物的检测，以期为临床医师在治疗决策时提供参考，使患者最大程度获益。

abstractsMolecular diagnosis is of enormous significance for the clinical diagnosis and treatment of hepatobiliary tumors. The expert group first released the "Expert Consensus for Clinical Application of Molecular Diagnosis on Hepatobiliary Tumors" in 2020. The introduction of this consensus has promoted the standardized application of molecular diagnostic technology in the clinical work of hepatobiliary tumors and improved the diagnosis and treatment capabilities of clinical physicians for hepatobiliary tumors. Research on hepatobiliary tumors has gradually been carried out in recent years, with the continuous publication of new research results. Hence, the expert group updated this consensus on the basis of the latest research progress, the original consensus, with a focus on the detection of molecular markers for targeted and immunotherapy of hepatobiliary tumors, in order to provide a reference for clinical physicians in treatment decisions and maximize the benefits for patients.